Clinical reference Biomarker Directory
Back to directory

Anti-acetylcholine receptor antibody

Established

Anti-AChR antibody is the primary diagnostic marker for myasthenia gravis.

Also known as Anti-AChR antibody AChR-Ab
In plain language

This antibody attacks the connection between nerves and muscles, causing myasthenia gravis. A positive test confirms the diagnosis for most patients, but the antibody level doesn't reliably track how well someone is doing, so doctors watch symptoms, not just the number.

Biomarker & context

Anti-acetylcholine receptor (AChR) antibodies target receptors at the neuromuscular junction and are the primary diagnostic marker for myasthenia gravis (MG), an autoimmune disorder causing fluctuating muscle weakness.

What it indicates

Positive AChR antibodies confirm MG in about 80% of generalized cases; the remaining ~10% of "seronegative" patients may instead have anti-MuSK or anti-LRP4 antibodies, and roughly 10% remain antibody-negative on all current tests.

Diagnosis & clinical testing

Measured via radioimmunoassay (gold standard) or cell-based assays; clustered cell-based assays are gaining use for detecting seronegative cases missed by standard testing.

Guiding treatment

Antibody titer is not a reliable pharmacodynamic biomarker — studies show weak-to-no correlation between titer changes and individual symptom severity, so clinicians should not rely on titer trends alone to judge treatment response.

Clinical significance

Confirms diagnosis in ~80% of generalized MG; titer level does not reliably track disease severity.

References
  1. Lee, I., & Sanders, D. (2021). Rethinking the utility of acetylcholine receptor antibody titer as a pharmacodynamic biomarker for myasthenia gravis. Muscle & Nerve.